Biotechnology

Agios Pharmac

US Bank Securities Analyst Reiterates Buy Rating on Agios Pharma Stock

Agios Pharmac released FY2026 Q1 earnings on April 29 Pre-Market (EST), actual revenue USD 20.75 M (forecast USD 13.34 M), actual EPS USD -1.6899 (forecast USD -1.8034)

Agios Pharmaceuticals Reports Q1 Revenue Doubling and Plans to Submit New Drug Application

Agios Pharmac FY2026 Q1 Earnings Release on April 29 Pre-Market EST, Forecast Revenue USD 13.65 M, EPS USD -1.7982

Agios Pharmac released FY2025 Q4 earnings on February 12 During-Market (EST), actual revenue USD 19.97 M (forecast USD 12.06 M), actual EPS USD -1.8515 (forecast USD -1.9533)

Agios Pharmac released FY2025 annual earnings during market hours on February 12 (EST), actual revenue USD 54.03 M (forecast USD 46.12 M), actual EPS USD -7.1203 (forecast USD -7.0621)

Agios Pharmaceuticals Reports 2025 Product Revenue Exceeding Expectations and Plans to Launch New Drug AQVESME in 2026

Agios Pharmac to Release FY2025 Q4 Earnings on February 12 During-Market (EST), Forecast Revenue USD 12.06 M, EPS USD -1.9533

Agios Pharmaceuticals Presents 2026 Growth Plan at JPM Healthcare Conference

Agios Pharmaceuticals to Release Strategic Update on January 14th

Agios Pharmaceuticals Announces 2026 Strategic Priorities, Advances Rare Disease Pipeline

Agios Pharmaceuticals CEO Disposes of Company Common Stock

FDA Approves Agios' Thalassemia Drug Aqvesme and Vanda Pharmaceuticals' Motion Sickness Drug Nereus

Agios Pharmaceuticals' stock price fell by 5.3%

Andrew Berens Maintains Buy Rating for Agios Pharmaceuticals with a Target Price of $40

Goldman Sachs Raises Agios Pharmaceuticals Target Price and Analyzes Core Drug Prospects

TD Cowen Analyst Maintains Buy Rating on Agios Pharma

Agios Pharmaceuticals Announces FDA Approval of AQVESME for Thalassemia

Agios Pharmaceuticals' Pyrukynd Expected to Receive FDA Approval

H.C. Wainwright Analyst Reiterates Buy Rating on Agios Pharma and Sets Target Price

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AGIO

Agios Pharmaceuticals reported a strong launch of AQVESME for thalassemia and submitted a supplemental new drug application for sickle cell disease. CEO Brian Goff highlighted early traction and a focus on rare hematologic diseases. The company is pursuing an accelerated approval pathway with the FDA for sickle cell, supported by a confirmatory trial. Agios remains confident in its data despite recent competitor results and expects to provide updates on prescriptions and revenue as the launch matures.

Market Beat

Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances

Bank of America Securities analyst Alec Stranahan has reaffirmed a Buy rating for Agios Pharma (AGIO) with a price target of $41.00, while the shares closed at $28.42. Stranahan, who focuses on the Healthcare sector, has an average return of 10.3% and a success rate of 52.78%. Additionally, Agios Pharma received a Buy rating from Truist Financial, while RBC Capital maintained a Hold rating.

Tip Ranks

Bank of America

Moderna

Beam Therapeutics

Revolution Medicines

Truist Financial

ROYAL BANK OF CANADA

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO)

ALKS

Healthcare stocks experienced gains on May 12, 2026, with the NYSE Healthcare Index up 2.1% and the State Street Healthcare Select Sector SPDR ETF rising 2.2%. Alkermes saw a 5% increase after positive trial results for its Lumryz oral suspension. RBC Capital Markets upgraded Sonida Senior Living's price target to $45, noting its strong Q1 results, leading to a 1.5% rise in shares. Agios Pharmaceuticals rose 1% after submitting a New Drug Application for mitapivat to treat sickle cell disease.

Fidelity

Alkermes

Health Care Select Sector SPDR

iShares Biotechnology ETF

Sonida Senior Living

Sector Update: Healthcare Stocks Gain in Afternoon Trading

Agios Pharmaceuticals has submitted a supplemental New Drug Application (sNDA) to the FDA for accelerated approval of mitapivat in treating sickle cell disease. This follows an agreement with the FDA on a confirmatory trial aimed at demonstrating the drug's clinical benefits in reducing transfusion burden. The trial will enroll approximately 159 patients and is based on positive results from the RISE UP Phase 3 trial. Agios anticipates receiving notice of the sNDA filing acceptance in Q3 2026, marking a significant milestone for sickle cell disease treatment.

StockTitan

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease | AGIO Stock News

State of New Jersey Common Pension Fund D acquired 47,414 shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) valued at approximately $1.29 million during the 4th quarter. Other institutional investors also adjusted their positions in the company. Agios Pharmaceuticals reported a quarterly revenue of $20.75 million, exceeding estimates, and had a negative EPS of ($1.69). Analysts have mixed ratings on the stock, with an average target price of $41.56. Insider Tsveta Milanova sold 3,262 shares recently, reducing their ownership by 6.51%.

Manulife Financial

Citigroup

Goldman Sachs

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D

Agios Pharmaceuticals' shares surged 11.2% this week following strong earnings and the U.S. launch of Aqvesme. The company faces competition from Novo Nordisk's etavopivat in treating sickle cell disease, but expects significant pipeline updates in 2026, particularly for tebapivat. Agios has seen sales grow to $20.7 million, driven by Aqvesme's performance. Despite challenges with mitapivat's competition, management is optimistic about future approvals and demand for their products.

nasdaq

Novo Nordisk AS

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

Defiance Daily Target 2X Long NVO ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

NVIDIA

Intel

Netflix

S&P 500

Nasdaq

NVIDIA Corporation

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)

RBC Capital has maintained a Hold rating on Agios Pharma (AGIO) with a price target of $28.00, while the shares closed at $28.05. Analyst Luca Issi has an average return of -3.4% and a 36.90% success rate. J.P. Morgan also issued a Hold rating, while Truist Financial maintained a Buy rating on the stock.

Amgen

Wave Life Sciences

Ascendis Pharmac

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

RBC Capital Sticks to Its Hold Rating for Agios Pharma (AGIO)

Agios Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.

benzinga_article

Agios Pharmaceuticals (NASDAQ:AGIO) shares surged to $26.50 after reporting better-than-expected earnings of ($1.69) per share, surpassing estimates of ($1.82). Revenue reached $20.75 million, exceeding the $13.91 million forecast. Analysts have mixed ratings, with six recommending a buy and four a hold. Insider trading saw significant sales to cover tax obligations. Institutional investors have increased their stakes, with AQR Capital Management boosting its position by 66.8%. The stock has a market cap of $1.64 billion and is trading up 11.0%.

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up  on Earnings Beat

Earnings Watch

Agios Pharmac | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 20.75 M

Agios Pharmac(AGIO.US)